Geopolitical friction complicates the banking and shipping sectors, creating indirect hurdles for medical imports. Even though humanitarian goods like insulin and chemotherapy agents technically fall under broad sanctions exemptions, the reality on the ground is much messier. Most international banks refuse to process any transactions involving Iranian entities to avoid accidental violations of US secondary sanctions. This financial freeze makes it incredibly difficult for Iranian importers to pay foreign pharmaceutical companies for life-saving medications.
As supply chains tighten, shortages of specific oncology drugs become common. When specialized medications cannot arrive on schedule, hospitals often turn to less reliable, unverified sources. This shift increases the risk of counterfeit or sub-standard medicine entering the market. For a patient managing diabetes, a slight change in the quality or purity of insulin can lead to catastrophic metabolic shifts. Similarly, interruptions in oncology protocols can diminish the efficacy of cancer treatments.
Logistical delays add further complications. Freight costs rise as shipping lines avoid regional ports. Ultimately, the civilian population bears the brunt of these systemic delays. A patient may find the correct medication is unavailable, or the version they do find is several months past its expiration date due to transit bottlenecks.
